Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices 9163 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier: OS–0990–new] 

Agency Information Collection 

Request. 60-Day Public Comment 

Request 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before April 9, 2024. 

ADDRESSES: Submit your comments to 

Sherrette.Funn@hhs.gov or by calling 

(202) 264–0041 and PRA@HHS.GOV. 

FOR FURTHER INFORMATION CONTACT: 

When submitting comments or 

requesting information, please include 

the document identifier 0990–New–60D 

and project title for reference, to 

Sherrette A. Funn, email: 

Sherrette.Funn@hhs.gov, PRA@

HHS.GOV or call (202) 264–0041 the 

Reports Clearance Officer. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collection: Research 

Misconduct and Noncompliance in 

Clinical Trials and Translational 

Research. 

Type of Collection: New. 

OMB No.: 0990–XXXX. 

Abstract: The Department of Health 

and Human Services (HHS) Office of 

Research Integrity (ORI) has partnered 

with the Office for Human Research 

Protections (OHRP) to launch this data 

collection effort to better understand 

how to serve those who might benefit 

from additional education and resources 

to improve research integrity. ORI and 

OHRP have found that researchers, 

Institutional Review Board (IRB) Chairs, 

Research Integrity Officers (RIOs), 

Human Protections and Compliance 

Officers, and Human Protections 

Administrators, who oversee the 

conduct of research involving human 

research subjects, may struggle with 

identifying reportable noncompliance or 

unanticipated problems, protocol 

violations, protocol deficiencies, and 

falsifications and fabrications of data 

and methods in that research. Failure to 

recognize these concerns may result in 

noncompliance, protocol violations and 

research misconduct not being 

adequately addressed; falsified and/or 

fabricated methods, data, and results 

that may be published or used to obtain 

federal funding; human research 

subjects being harmed; and/or Public 

Health Service (PHS) funds not being 

protected. 

This data collection is a new request 

and includes an online survey 

instrument used with stakeholders 

holding positions at institutions holding 

a Federalwide Assurance (FWA) and/or 

operating an IRB, and is designed to 

identify barriers in the identification, 

evaluation, and reporting of potential 

research misconduct, protocol 

violations, reportable noncompliance, 

and unanticipated problems in research 

that involves human subjects. This data 

collection is intended to assist ORI and 

OHRP in developing approaches to 

improve how to identify and distinguish 

incidents that are reportable to ORI and 

OHRP from those that do not require 

reporting to these offices. This 

information is also intended to give 

RIOs, IRBs, human protections 

administrators, compliance officers, and 

other institutional officials involved 

with human subjects’ research insight 

into how they can strengthen their 

policies and procedures for identifying, 

evaluating, and/or communicating 

potential research misconduct and 

reportable noncompliance and 

unanticipated problems by identifying 

gaps, barriers, and areas in which 

communication and education may 

need to be enhanced within their 

institution. 

ANNUALIZED BURDEN HOUR TABLE

Forms 

(If necessary) 

Respondents 

(If necessary) 

Number of 

respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total 

burden 

hours 

ORI/OHRP Survey ............................................................... ........................ 1165 1 20/60 388 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2024–02649 Filed 2–8–24; 8:45 am] 

BILLING CODE 4150–36–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the National Vaccine 

Advisory Committee 

AGENCY: Office of Infectious Disease and 

HIV/AIDS Policy, Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) hereby gives notice that 

the National Vaccine Advisory 

Committee (NVAC) will hold an inperson meeting. The meeting will be 

open to the public and public comment 

will be heard during the meeting. 

DATES: The meeting will be held 

February 22–23, 2024. The confirmed 

meeting times and agenda will be 

posted on the NVAC website at http:// 

www.hhs.gov/nvpo/nvac/meetings/ 

index.html as soon as they become 

available. 

ADDRESSES: Instructions regarding 

attending this meeting will be posted 

online at: http://www.hhs.gov/nvpo/ 

nvac/meetings/index.html at least one 

week prior to the meeting. Preregistration is required for those who 

wish to attend the meeting in person or 

participate in public comment. Please 

register at http://www.hhs.gov/nvpo/ 

nvac/meetings/index.html. 

FOR FURTHER INFORMATION CONTACT: Ann 

Aikin, Acting Designated Federal 

Officer, Office of Infectious Disease and 

HIV/AIDS Policy, U.S. Department of 

Health and Human Services, Tower 

Building, Room, 1101 Wootton 

Parkway, Rockville, MD 20852. Email: 

nvac@hhs.gov. Phone: 202–795–7697. 

SUPPLEMENTARY INFORMATION: Pursuant 

to section 2101 of the Public Health 


ddrumheller on DSK120RN23PROD with NOTICES1
9164 Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices 

Service Act (42 U.S.C. 300aa–1), the 

Secretary of HHS was mandated to 

establish the National Vaccine Program 

to achieve optimal prevention of human 

infectious diseases through 

immunization and to achieve optimal 

prevention against adverse reactions to 

vaccines. The NVAC was established to 

provide advice and make 

recommendations to the Director of the 

National Vaccine Program on matters 

related to the Program’s responsibilities. 

The Assistant Secretary for Health 

serves as Director of the National 

Vaccine Program. 

During this meeting, NVAC will hear 

presentations to support the recent 

charge on innovation from Admiral 

Rachel L. Levine, MD, the Assistant 

Secretary for Health and Director of the 

National Vaccine Program. NVAC will 

also hear presentations on recent surges 

in measles cases, the Vaccines for 

Children’s Program, real uses of 

artificial intelligence to support 

vaccination efforts, and supply chains. 

Presenters will also cover ways to 

improve immunization of children, 

adults, and pregnant people. Please note 

that agenda items are subject to change, 

as priorities dictate. Information on the 

final meeting agenda will be posted 

prior to the meeting on the NVAC 

website: http://www.hhs.gov/nvpo/ 

nvac/index.html. 

Members of the public will have the 

opportunity to provide comment at the 

NVAC meeting during the public 

comment period designated on the 

agenda. Public comments made during 

the meeting will be limited to three 

minutes per person to ensure time is 

allotted for all those wishing to speak. 

Members of the public may also submit 

written comments. Written comments 

should not exceed three pages in length. 

Individuals planning to submit 

comments should email their written 

comments or their request to provide a 

comment during the meeting to nvac@

hhs.gov at least five business days prior 

to the meeting. 

Dated: January 11, 2024. 

Ann Aikin, 

Acting Designated Federal Official, Office of 

the Assistant Secretary for Health. 

[FR Doc. 2024–02636 Filed 2–8–24; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Digestive Diseases and 

Nutrition C Study Section Digestive Diseases 

and Nutrition C Study Section. 

Date: March 13–15, 2024. 

Time: 5:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, NIDDK 

Democracy II, Suite 7000A, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Peter J. Kozel, Ph.D., 

Scientific Review Officer, NIDDK/Scientific 

Review Branch, National Institutes of Health, 

6707 Democracy Blvd., Room 7009, 

Bethesda, MD 20892, (301) 594–4721, 

kozelp@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: February 6, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02697 Filed 2–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Understudied Proteins 

Associated with Rare Diseases (R03) Review. 

Date: May 30, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, 

Bethesda, MD 20892. 

Contact Person: Ming Yan, MD, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

National Center for Advancing Translational 

Sciences, National Institutes of Health, 6701 

Democracy Boulevard, MSC 4874, Bethesda, 

MD 20892, (301) 827–4312, ming.yan@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: February 5, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02651 Filed 2–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Mental Health Special Emphasis Panel 

BRAIN K99, March 6, 2024, 11:00 a.m. 

to March 06, 2024, 6:30 p.m., National 

Institutes of Health, Neuroscience 

Center, 6001 Executive Boulevard, 

Rockville, MD 20852 which was 

published in the Federal Register on 

February 2, 2024, FR Doc. 2024–02045, 

89 FR 7403. 

The meeting date has changed from 

March 6, 2024, to March 15, 2024. The 


ddrumheller on DSK120RN23PROD with NOTICES1